Navigation Links
Bioenergy Life Science Retains Xsto Solutions to Market D-Ribose
Date:12/11/2008

MINNEAPOLIS, Dec. 11 /PRNewswire/ -- Bioenergy Life Science -- The Ribose Company -- has announced that it has retained Xsto Solutions, LLC, to market Bioenergy D-Ribose(TM) in the Eastern U.S. D-Ribose is a naturally-occurring monosaccharide the body uses to stimulate the synthesis of adenosine triphosphate (ATP) -- an essential energy compound.

"Collaborating with Xsto Solutions will enhance our efforts toward expanding D-Ribose into the marketplace," said Kathy Lund, vice president marketing and sales of Bioenergy Life Science, Ribose Ingredient Division. "D-Ribose is already included in over 100 functional foods and beverages. Aligning ourselves with Xsto Solutions means that more companies will incorporate this natural energy booster."

"Bioenergy D-Ribose is perhaps the most important nutritional discovery of the decade," says Dan Murray, Xsto Solutions vice president of business development. "We're very excited about aggressively expanding the exposure of D-Ribose within the supplement, functional foods and sports nutrition industries."

Although ribose is produced by the body naturally to regulate the synthesis of ATP, it cannot be replenished fast enough during certain forms of demanding exercise. When added to foods and dietary supplements, ribose enhances the body's natural process of energy synthesis. It helps reduce the loss of energy during stress and accelerates energy and tissue recovery.

Bioenergy, which recently achieved GRAS (generally recognized as safe) status for D-Ribose from the U.S. Food and Drug Administration, has amassed a large body of scientific literature regarding uses of ribose for people across all age and health categories. The company has more than 40,000 customers for its proprietary Corvalen(R) products alone, and millions worldwide use Bioenergy D-Ribose in other functional foods like energy bars (Detour, FastFuel, Marathon) and beverages (SoBe Adrenaline Rush, Vitamin Water, Snapple Antioxidant Water).

Bioenergy, Inc. (http://www.bioenergy.com) is a privately held, Minneapolis-based life sciences company whose core technology lies in the development and commercialization of products based on the physiological benefits of D-Ribose for health and wellness. In addition to a pharmaceutical subsidiary, Bioenergy has two other companies. Bioenergy Life Science, Inc. manufactures and sells D-Ribose as an ingredient to nutraceutical firms for beverages and foods; as a medical food through doctors and clinics; and as a dietary supplement for energy recovery (reduces fatigue, muscle pain, soreness and stiffness following exercise). Viacell, LLC is developing technology related to the enhancement of blood components.

Xsto Solutions, LLC (http://www.xstosolutions.com), was established in 2004 and is headquartered in Morristown, New Jersey. Xsto's core focus is bringing a small number of new science-supported nutritional ingredients to the dietary supplement and functional food market. Xsto personnel have successfully and profitably launched new products, driving sales by acting as US-based sales and marketing partners. Xsto has also partnered with small-to medium-sized dietary supplement manufacturers to increase sales and marketing focus.


'/>"/>
SOURCE Bioenergy Life Science
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. U.S. Research Funding Continues to Flatten as U.S. Health Costs Climb - in August 31 Science
2. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
3. Edwards Lifesciences to Present at the Bear Stearns 20th Annual Healthcare Conference
4. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
5. HealthFitness CEO Supports Move Toward Cultural Shift, and Science-Based Health Management Programming
6. Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
7. John B. Buse, MD, PhD of Chapel Hill, NC, Elected American Diabetes Association President, Medicine & Science
8. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
9. SAMHSA Announces First Science and Service Award Winners
10. Novavax CEO to Present at the 2007 UBS Global Life Sciences Conference
11. Replidyne Pipeline Featured at 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty ... Barry M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... and the most handsome men, look naturally attractive. Plastic surgery should be invisible.” ...
(Date:6/24/2016)... Frederick, Maryland (PRWEB) , ... June 24, 2016 ... ... Mid-Atlantic Angels is actively feeding the Frederick area economy by obtaining investment capital ... support over the past 2½ years that have already resulted in more than ...
(Date:6/24/2016)... ... 2016 , ... Venture Construction Group (VCG) sponsors Luke’s Wings ... at the Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The ... members that have been wounded in battle and their families. Venture Construction Group is ...
(Date:6/24/2016)... ... June 24, 2016 , ... Advanced Plastic Surgery ... Arizona pageant as its official Medspa Sponsor. Dr. Josh Olson, a board-certified plastic ... , Dr. Olson says the decision to support the pageant in an ...
(Date:6/24/2016)... ... June 24, 2016 , ... To succeed under value-based ... however, are unsure how to move forward, given the need to sustain current ... forward tailored to an organization’s specific needs. , PYA Principal Martie Ross states, ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
Breaking Medicine Technology: